GÖTEBORG, Sweden and TUSCON, Ariz., Dec. 05, 2018 (GLOBE NEWSWIRE) — TATAA Biocenter, Europe’s leading provider of genomic services, and HTG Molecular Diagnostics, Inc (HTG) (Nasdaq: HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the expansion of TATAA Biocenter’s next-generation sequencing (NGS) offerings with HTG’s unique HTG EdgeSeq system.
“The HTG EdgeSeq system is a conceptual breakthrough in targeted RNA sequencing offering superior sensitivity and specificity to traditional RNASeq approaches,” said Dr. Mikael Kubista, founder and CEO of TATAA Biocenter. “We have validated the HTG EdgeSeq system in the European CANCER-ID consortium (www.cancer-id.eu), and we are proud to be among the first in Europe offering RNA sequencing service with this new platform.”
Jean Claude Gerard, HTG’s Vice President of European Operations stated, “HTG is thrilled to partner with TATAA Biocenter on extending TATAA’s current genomic service and hands-on NGS training course offerings. With the growing need for broad and reproducible gene-expression analysis from ever decreasing sample sizes, HTG’s extraction-free HTG EdgeSeq technology enables sensitive profiling of very limited samples. We believe these capabilities will open new perspectives in the field of liquid biopsy and tumor profiling and help advance precision medicine.” Mr. Gerard concluded, “A key to making this happen is HTG, as a technology provider, making education and training one of its key missions. Joining forces with TATAA Biocenter reflects a next step in our ongoing commitment to this effort.”
About TATAA Biocenter:
TATAA Biocenter is world’s largest organizer of hands-on training in molecular analyses and Europe’s leading provider of nucleic acid analysis services in compliance with ISO17025 standard. In 2007 TATAA Biocenter was the first company in Europe to provide digital PCR services to researchers and published in 2008 one of the first papers featuring an application of digital PCR on a high throughput platform (Nucleic Acids Research 36: 387, 2008). TATAA experts also co-authored the Guidelines for Minimum Information for Publication of Quantitative Digital PCR Experiments (Clinical Chemistry 59:6, 2013). Founded in 2001, TATAA has permanent facility in Gothenburg, Sweden, and Prague, Czech Republic. In 2013 TATAA was presented the Frost & Sullivan Award for Customer Value Leadership as Best-in-Class Services for Analyzing Genetic Material. Visit us at www.tataa.com.
About HTG Molecular:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level. Visit us at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the benefits of the partnership between HTG and TATAA. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the partnership with TATAA may not function or provide benefits to our customers as expected; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 525-7754
Email: [email protected]
